Estimaciones de analistas de Wall Street para Savara Inc. (SVRA): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 9 |
| Mantener | 2 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 11 |
| Calificación media (1-5) | 0.82 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.16 | ||
| 2026-08-11 | $-0.16 | $-0.14 | -13.3% |
| 2026-05-12 | $-0.15 | $-0.14 | -7.1% |
| 2026-03-13 | $-0.13 | $-0.12 | -8.3% |
| 2025-11-12 | $-0.14 | $-0.13 | -7.7% |
| 2025-08-13 | $-0.14 | $-0.12 | -16.7% |
| 2025-05-13 | $-0.12 | $-0.12 | +0.0% |
| 2025-03-27 | $-0.13 | $-0.11 | -18.2% |
Ratios de valoración
| Precio / Valor contable | 9.09 |
| EV / EBITDA | -7.83 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $400000 | 0 | 0 | 0 | $257000 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | $363000 | $526000 | $38.8M | $35.0M | $29.0M | $27.9M | $44.3M | $78.0M | $245000 |
| Beneficio Bruto | $400000 | -$363000 | -$526000 | -$38.8M | -$34.8M | -$29.0M | -$27.9M | -$44.3M | -$78.0M | -$245000 |
| I+D | $8.2M | $18.5M | $37.2M | $38.8M | $35.0M | $29.0M | $27.9M | $44.3M | $78.0M | $81.4M |
| Generales y Administrativos | $2.8M | $11.1M | $10.7M | $12.9M | $12.0M | $12.3M | $10.9M | $15.7M | $25.0M | $42.1M |
| Gastos Operativos | $11.3M | $30.0M | $48.4M | $40.2M | $14.5M | $12.5M | $11.0M | $15.7M | $25.2M | $123.3M |
| Beneficio Operativo | -$10.9M | -$30.0M | -$70.0M | -$79.0M | -$49.3M | -$41.5M | -$38.8M | -$60.0M | -$103.2M | -$123.5M |
| EBITDA | -$10.5M | -$31.9M | -$69.5M | -$50.4M | -$45.9M | -$40.5M | -$38.0M | -$59.1M | -$102.3M | -$118.6M |
| Gastos por Intereses | $468000 | $1.2M | $11000 | $70000 | $1.5M | $2.3M | $88000 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$11.3M | -$33.4M | -$70.0M | -$78.2M | -$49.6M | -$43.0M | -$38.1M | -$54.7M | -$95.9M | -$118.8M |
| Impuestos | -$357000 | -$3.6M | -$8.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$10.9M | -$29.8M | -$61.5M | -$78.2M | -$49.6M | -$43.0M | -$38.1M | -$54.7M | -$95.9M | -$118.8M |
| BPA | $-3.27 | $-1.70 | $-1.85 | $-2.62 | $-0.84 | $-0.32 | $-0.25 | $-0.33 | $-0.48 | $-0.53 |
| BPA Diluido | $-3.27 | $-1.70 | $-1.85 | $-2.62 | $-0.84 | $-0.32 | $-0.25 | $-0.33 | $-0.48 | $-0.53 |
| Acciones en Circulación (Diluidas) | $3.3M | $17.5M | $33.3M | $40.0M | $59.3M | $133.9M | $152.8M | $165.2M | $198.2M | $222.4M |
Precio
| Precio | $5.13 |
| Capitalización | $1.1B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: BCAX · EYPT · GERN · GHRS · KURA · NBTX · PROK
Explorar sector: Healthcare · Biotechnology
Más secciones de SVRA: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones